Acadia reports DAYBUE net sales for 2025 and 2026 guidance
Filed with ASX · · 4 pages · English
Neuren Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Neuren Pharmaceuticals
- Pause in Trading
- Neuren to commence new on-market share buy-back program
- First patient dosed in Neuren PMS Phase 3 trial
- Neuren receives US FDA meeting feeback for HIE and PTHS
- Trading Halt
Later from Neuren Pharmaceuticals
- Appendix 4E and 2025 full year accounts
- 2025 royalty income A$65m, profit after tax A$30m
- Acadia confirms plan to request CHMP re-examination
- DAYBUE STIX now broadly available in US for Rett syndrome
- Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals